Oncodiag: Cloud-based AIML platform to support medical decision-making in early detection of cancer

The main articles are:

• Cancer diagnosis
• SaaS - History. Philosophy. Development drivers
• Medical Decision Support Systems (CDS)

Cloudy AIML- a platform for supporting medical decision-making in early detection of oncological diseases is intended for medical centers, clinics and doctors. The platform allows with a high degree of probability (> 90%) to identify cancer at an early stage, including testing and making a medical decision.

2023: Obtaining a medical license

The Oncodiag company received a medical license as part of the Cloud AIML Platform for Supporting Medical Decision-Making in Early Detection of Oncological Diseases project. This was announced on February 22, 2023 to Zdrav.Expert by the Skolkovo Foundation.

As of February 2023, the Oncodiag platform can perform up to 300 thousand analyzes per year. It will allow organizing the collection of data to fill the decision-making system to identify the location of the tumor, as well as expand the range of services provided within the framework of the non-state health care system.

At the first stage of the project, from 2023, Oncodiag will conduct tests at the level of an innovative SA-62 marker developed at Skolkovo by Jayvis Diagnostics. Studies have shown that this Marker.ru most effectively (up to 95% accuracy) detects epithelial tumors in the early stages of cancer (up to 90% of all cases of cancer), including such as lung, ovarian, prostate, breast, colorectal cancer.

Russian AI-platform for early oncodiagnosis received a medical license
Photo: thevoicemag.ru

'The 'Jayvis Diagnostics' team has set the ambitious goal of creating a test for early detection of cancer. It should be noted that the use of an additional marker CA-15.3 gives the CA-62 marker developed by Jayvis Diagnostics specificity to the location of cancer, which makes it possible to significantly simplify the procedure for screening breast cancer in the early stages, conducting an analysis only on the basis of a blood test. The Skolkovo Foundation sees that the task is being solved successfully. We believe that the introduction of companies into the structure of practical healthcare will be on the shoulder, "- Sergey Shcherbakov, project manager of the cluster of biomedical technologies of the Skolkovo Foundation.

According to Oncodiag, testing for a high level of the CA-62 marker is relevant both for prescreening, which detects people at high risk of having early cancer, and for monitoring those who have a genetic predisposition, as well as for detecting relapses of cancer in those who have recovered.

"In our team, we connect practical health care and the development of medical decision-making systems in the field of early detection of the second due to mortality of the disease - cancer. We believe that regular monitoring using our test is a cure for the fear of cancer, which is widespread in the population, "said Oleg Kreidenko, CEO of OnkoDiag.

In addition, some sectors of the Russian economy with high professional risks can effectively introduce the test into their medical examination system. This is important for workers in contact with ionizing and ultraviolet radiation, chemical agents and other unfavorable factors, according to the Skolkovo Foundation.

The Oncodiag company plans to cooperate with family doctors, therapists, oncological specialists, as well as with medical centers in Moscow, the Moscow Region and St. Petersburg at the first stage.